Wed, Mar 4, 2015, 2:03 AM EST - U.S. Markets open in 7 hrs 27 mins


% | $
Quotes you view appear here for quick access.

Neostem, Inc. Message Board

trendbase 9 posts  |  Last Activity: Jan 26, 2015 5:23 PM Member since: Nov 27, 2007
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • trendbase trendbase Jan 26, 2015 5:23 PM Flag

    This my friend is a sinking ship ! Jumped ship today !!!!! Good Luck !!!!

  • This is getting nauseous.

  • Reply to

    Palm Springs system highly utilized

    by afibguy Jan 23, 2015 3:16 PM
    trendbase trendbase Jan 24, 2015 3:34 PM Flag

    So you are saying that in this day and age we still need to depend on someones manual ablation even though we live is an technology advanced society. Sad.

    Sentiment: Buy

  • Reply to

    Could we become a takeover target…?

    by miserspet Jan 23, 2015 12:33 PM
    trendbase trendbase Jan 24, 2015 9:45 AM Flag

    You have to wonder why they have been driving the share price down so hard ?

    Sentiment: Buy

  • Reply to

    Palm Springs system highly utilized

    by afibguy Jan 23, 2015 3:16 PM
    trendbase trendbase Jan 24, 2015 8:59 AM Flag

    Great article." Implementing a Stereotaxis Program: Interview with Dr. Hetal Bhakta"
    "I was also particularly impressed with their safety profile compared to the other robotic technologies. Their precision and navigation accuracy was also far superior"

    Sentiment: Buy

  • trendbase by trendbase Jan 22, 2015 6:00 PM Flag

    Why do suppose Gesiuris Asset Management picked up 240,000, 11/30/2014
    Does Sterotaxis have any potential sales in Spain ?

  • Cleveland Clinic
    4 Top Questions About Radiofrequency Ablation for Afib Answered
    This treatment can help when medicines fail
    By Heart & Vascular Team | 1/15/15 12:00 p.m.
    If medications you’re taking for atrial fibrillation (afib) aren’t working anymore, there is another option: radiofrequency ablation.
    In most patients, rapid electrical activity that starts in the pulmonary vein and spreads to the atrium of the heart triggers afib. Radiofrequency ablation is a procedure that applies electrical energy to the area around the pulmonary vein.
    “What radiofrequency ablation does is create roadblocks at the pulmonary vein to shield the atrium from the electrical activity that causes afib,” says cardiologist Walid Saliba, MD, Medical Director of the Center for Atrial Fibrillation at Cleveland Clinic.
    Although radiofrequency ablation has been used as a treatment method for afib since the late 1990s, it is now being more widely accepted as a first-line therapy, or first treatment.
    “Traditionally, afib has been treated with medications to slow the heartbeat or antiarrhythmics to suppress the afib,” says Dr. Saliba. “But medications have limitations and also side effects, and they only work to a certain extent. The likelihood of a particular medication still working after one year is about 50 percent at best.”

  • Reply to

    St. Jude Medical Begins Landmark Clinical Study

    by trendbase Jan 14, 2015 12:50 PM
    trendbase trendbase Jan 14, 2015 5:39 PM Flag

    We are talking about a whole new aspect in the treatment of cardiac arrhythmia for the reduction in Ventricular Tachycardia. Most ablation procedures within the U.S. has been focused around Atrial Fibrillation. V-tach opens up a completely new avenue for ablation procedures. This is great news for Stereotaxis.

    Sentiment: Strong Buy

  • January 07, 2015 11:30 AM Eastern Standard Time
    ST. PAUL, Minn.--(BUSINESS WIRE)--St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced the first patient enrollment in the STAR-VT (Substrate Targeted Ablation using the FlexAbility™ Ablation Catheter System for the Reduction of Ventricular Tachycardia) clinical trial, a prospective, multi-center, randomized study evaluating the safety and efficacy of the FlexAbility™ ablation catheter when used in ventricular tachycardia (VT) ablation procedures. The STAR-VT trial will assess whether combining targeted ablation with either an implantable cardiac defibrillator (ICD) or cardiac resynchronization therapy defibrillator (CRT-D) can reduce the incidence and economic burden of recurring ventricular arrhythmias better than treatment with either an ICD or CRT-D and medication alone.

    “We look forward to gathering evidence that supports our belief that the addition of catheter ablation in this patient population is a safer, more efficacious and cost effective option for patients than routine drug and implantable defibrillator therapy alone when treating complex ventricular arrhythmias.”

    “For many years, implantable cardioverter defibrillators have been one of the primary treatment options for patients with ventricular arrhythmias,” said Dr. Andrea Natale, executive medical director at the Texas Cardiac Arrhythmia Institute. “While these are life-saving therapies, patient risks associated with the recurrence of ventricular tachycardia, such as frequent shocks from an implantable defibrillator, still exist. This study is important because it may provide further evidence that ablation therapies are more effective than medication in suppressing recurring ventricular tachycardia and, with it, the freedom from shocks and repeat cardiovascular hospitalizations for my patients.”

    Sentiment: Strong Buy

3.99+0.19(+5.00%)Mar 3 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.